Nature Biotechnology

Papers
(The H4-Index of Nature Biotechnology is 111. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Single-cell RNA-seq keeps cells alive5238
Synthetic biologics provide a path to target bHLH transcription factors2462
Denmark invests in mucosal vaccines1367
Wireless microelectronic fibers to discover gut and brain pathways1140
Overcoming unpredictability in biotech patents by tailored claiming aligned with genuine enablement1043
Framework for predicting alloreactivity in hematopoietic cell transplants918
Bite-sized solutions800
Author Correction: Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion633
Human periportal liver assembloids566
People514
Cancer Moonshot aims at liquid biopsies514
Cellular shuttles put mislocalized proteins in their right place477
Diffusion model expands RoseTTAFold’s power440
Author Correction: Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew428
Establishing a commercial solution for extremely rare genetic diseases411
The lysosomal degraders399
Fluorescence microscopy resolution increases to near-atomic level383
Integrating medicine, engineering and business to educate early-stage researchers in cardiovascular device development374
TRGT-ing the dark genome to accurately characterize tandem repeats at scale369
Biopharma dives into tumor-seeking radioactive drugs356
Synthetic biology’s uncertain regulatory future in the wake of Loper Bright Enterprises v. Raimondo344
Fungal architecture is a thing, and it’s eye-catching319
Single-cell spatial pharmacobiology for imaging antibody-based therapies in solid tumors313
A competitive precision CRISPR method to identify the fitness effects of transcription factor binding sites285
Fresh from the biotech pipeline: FDA turmoil overshadows 2025 approvals284
Programming biology: next-gen AI firms raise billions to design better medicines275
Spatial CRISPR screens map total RNA in tissue269
Biotech news from around the world267
Orchestration of secondary metabolite production in Streptomyces species266
An optimized toolkit for prime editing258
Chem-map profiles drug binding to chromatin in cells251
Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism250
Democratizing knowledge representation with BioCypher245
High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition245
Generative models for protein structures and sequences241
An oncolytic virus–T cell chimera for cancer immunotherapy239
Dual SORT LNPs for multi-organ base editing236
Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy232
The world’s first CRISPR therapy is approved: who will receive it?219
Agentic AI and the rise of in silico team science in biomedical research214
Engineered serum markers for non-invasive monitoring of gene expression in the brain212
Droplet-based transcriptome profiling of individual synapses211
Behind the graduate mental health crisis in science210
Reflective multi-immersion microscope objectives inspired by the Schmidt telescope209
Programmable promoter editing for precise control of transgene expression208
Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates207
In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice205
A spatial view of tumor neoantigen recognition204
Engineering innate immune cells for cancer immunotherapy203
Automated reconstruction of whole-embryo cell lineages by learning from sparse annotations201
Predicting transcriptional outcomes of novel multigene perturbations with GEARS199
Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids198
Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome197
Single-cell nanobody-based profiles of multiple epigenetic modalities and chromatin velocity194
AI predicts cancer relapse from slides193
Biotech news from around the world189
The need for need-finding in medical education188
3Q22 — more malaise in the markets188
Biotech news from around the world183
People180
Decoding gene regulation with CRISPR perturbations178
Delix Therapeutics : psychedelics without the trip177
Sequence Display enables large-scale sequence–activity datasets for rapid protein evolution174
Computationally designed enzymes show potent catalytic activity173
Adrestia Therapeutics — Gene networks to the rescue170
Connecting research and clinical practice: training the next generation of translational scientists168
Mapping the patent landscape of cancer diagnostics164
GLP-1s surprise failure in Alzheimer’s163
Next-generation psychedelics: should new agents skip the trip?163
In vivo base editing reverses a neurodevelopmental disorder156
Lessons from biotech’s unscientific evolution156
Author Correction: The cost of drug patent expiration date errors155
David Baltimore (1938–2025)155
Hallucinating functional protein sequences154
Escaping analysis paralysis in medical training: from FRAZZLE to CALM148
Retraction Note: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN147
Precise DNA cleavage using CRISPR-SpRYgests146
Artificial miRNA slows Huntington’s144
Gains in early-onset dementia with progranulin open new paths for drug discovery142
HSV-1’s contribution as a vector for gene therapy141
Slaughter-free meat hits the grocery shelf140
Live cell imaging of signaling networks using a conventional microscope137
A retargeted recombinase for precise insertion of large DNA135
Mesenchymal thymic niche cells enable regeneration of the adult thymus and T cell immunity134
FDA approves first MASH drug133
Orna Therapeutics: circular logic131
Reply to ‘Methodological concerns and a lack of evidence for reforming regulatory exclusivities for pharmaceuticals’128
Improving metagenome binning by integrating intrinsic features and taxonomy127
Grand challenges in bioinformatics education and training127
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression126
Editor’s pick: Liberate Bio125
Considerations for the future of in vitro gametogenesis in fertility care125
Prediction of peptide mass spectral libraries with machine learning125
A language model beats alphafold2 on orphans124
Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice121
Delivering 3 billion doses of Comirnaty in 2021121
The promises and challenges of neoantigen cancer vaccines121
Detection of mosaic and population-level structural variants with Sniffles2119
Building synthetic chromosomes one yeast at a time: insights from Sc2.0119
2022 – toughing out the trough119
A strategy to load, rethread and read protein sequences through a nanopore119
Drug pipeline 4Q22 — sticking around118
Biotech news from around the world118
Lab-made antibody stops malaria117
Forum: Boyden and Danzl117
Tension-tuned receptors for synthetic mechanotransduction and intercellular force detection117
Unpaired data as a first-order challenge in single-cell and spatial proteomics115
The global patent landscape of optogenetics: current advances, challenges and opportunities114
The devolution of biosimilars regulations114
Enzymatic synthesis of RNA oligonucleotides113
Prediction of prime editing insertion efficiencies using sequence features and DNA repair determinants112
How will generative AI disrupt data science in drug discovery?111
An update on patent issues regarding antibody–drug conjugates111
Genome-edited farm animals from haploid stem cells111
0.075568914413452